Question 1

What are the potential benefits of adding capecitabine to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients clinical trial (NCT03561740). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this trial compare to other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients clinical trial (NCT03561740). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from the metronomic capecitabine?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients clinical trial (NCT03561740). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients clinical trial (NCT03561740). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients clinical trial (NCT03561740). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my overall health be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients clinical trial (NCT03561740). Contact the study team or your healthcare provider for specific answers.

What this study is about